Stockscreener 앱 받기
53.90
2.77%
1.485
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb stock rating upgraded to Buy at BofA on pipeline strength - Investing.com UK
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions - Markets Financial Content
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More - 24/7 Wall St.
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | - GuruFocus
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Pitcairn Co. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Checkpoint Inhibitors Market Is Going to Boom |Bristol-Myers Squibb • Merck & Co. - openPR.com
Caldwell Trust Co Makes New $1.70 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum - Yahoo Finance
Bristol-Myers Squibb Shares Gain Momentum from Regulatory Advances - AD HOC NEWS
Buoyed by BMS milestones, Orum moves to build in-house clinical muscle - koreabiomed.com
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Coppell Advisory Solutions LLC Makes New $1.90 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Birchview Capital LP Has $14.97 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by AQR Capital Management LLC - MarketBeat
BMY Stock Rises: Analyst Upgrade to Buy & Opdivo FDA Priority Review | Dec 12, 2025News and Statistics - IndexBox
Why Bristol-Myers Squibb (BMY) Stock Is Up Today - Finviz
Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review - Oncodaily
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street's 2026 Focus - ts2.tech
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum? - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More - Yahoo Finance
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News - GuruFocus
Peapack Gladstone Financial Corp Reduces Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications - BioSpace
BNP Paribas Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application - pharmiweb.com
Bristol Myers Squibb (BMY) Seeks FDA Approval for Expanded Opdiv - GuruFocus
Bristol Myers wins FDA priority review for Opdivo (BMY:NYSE) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Featured in Sector Research Coverage - Kalkine Media
Nathan Pennell: Proud of Bristol Myers Squibb Team Presenting at ASH25 - Oncodaily
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma - Yahoo Finance
Bristol-Myers Squibb’s Strategic Moves: A Dual Focus on Shareholder Returns and Oncology Expansion - Ad-hoc-news.de
Bristol Myers (BMY) Declares Increased Quarterly Dividend for 20 - GuruFocus
Bristol Myers Squibb raises quarterly dividend by 1.6% - Investing.com Nigeria
Bristol-Myers Squibb Raises Quarterly Dividend by 1.6% to $0.63 a Share, Payable on Feb. 2, 2026 to Shareholders of Record on Jan. 2, 2026 - marketscreener.com
Bristol Myers Squibb Announces Dividend Increase - marketscreener.com
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) t - GuruFocus
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating - marketscreener.com
Peering Into Bristol-Myers Squibb Co's Recent Short Interest - Sahm
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound - Yahoo Finance
BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer - Citeline News & Insights
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
Bristol Myers Squibb Company $BMY Shares Bought by Investment Management Corp of Ontario - MarketBeat
BioNTech, Bristol Myers presents Phase 2 data for PD-L1xVEGF-A - TipRanks
66,361 Shares in Bristol Myers Squibb Company $BMY Bought by SVB Wealth LLC - MarketBeat
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - The Manila Times
Bristol Myers Squibb Company $BMY Stock Position Raised by Axa S.A. - MarketBeat
Analysts Project Modest Upside To Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb (BMY) Is Up 5.1% After Expanded Breyanzi MZL Approval Has The Bull Case Changed? - simplywall.st
Bristol Myers Squibb showcases new lymphoma therapy data at ASH meeting - Investing.com Canada
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 - Yahoo Finance
Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment - Finviz
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - Yahoo Finance
Bristol Myers Squibb a Top 25 Dividend Giant With 4.76% Yield (BMY) - Nasdaq
Bristol-Myers Squibb Settles China Bribery Case for $14.7 Million - Law.com
Bristol-Myers Squibb Stock Gains Momentum from Key Regulatory Approval - AD HOC NEWS
14 Best US Stocks to Buy for Long Term - Insider Monkey
California Public Employees Retirement System Has $286.27 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Bristol-Myers Squibb Just Got Crucial FDA Backing On Alzheimer’s Psychosis Program; What's NEXT? - Smartkarma
0.72%
0.12%
자본화:
|
볼륨(24시간):